NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Clinical Trials and a Complex Psychedelic Future w/ Dr. Alan K Davis
Clinical research often excludes the diversity of everyday life, making real-world access to psychedelic therapy look very different. As Dr. Alan Davis highlights, preparation and a safe therapeutic relationship are e...
Cambridge Isotope Laboratories, Inc. has applied to register as a bulk manufacturer of basic classes of controlled substances.
The Drug Enforcement Administration published the application on 24 September 2026. The notice opens a 90-day comment period, ending on 23 December 2026, and directs comments to the Justice Department or Regulations.gov.
Kasvu Therapeutics has raised €30 million in Series A funding led by Hadean Ventures to advance KTX-0141 towards clinical development for major depressive disorder.
The financing will support IND/CTA-enabling work and Phase 1/1b development of KTX-0141, a small-molecule TrkB positive allosteric modulator designed to enhance neuroplasticity without activating 5-HT2A. Kasvu expects...
Johnson & Johnson and Janssen won a four-patent case against Sandoz over Spravato, potentially delaying generic esketamine treatment until 2035.
The patents cover esketamine-based depression treatments, including dosing methods and a specific formulation. The case illustrates how companies may seek protection for established psychedelic-like compounds through ...
Eli-Elsohly Laboratories has applied to register as a bulk manufacturer of basic classes of controlled substances.
The Drug Enforcement Administration published the application on 24 September 2026, with a comment period ending on 23 November 2026. Further drug information is provided in the supplementary information.
Ensysce Biosciences submitted the CYBIO_001 protocol for a Phase 2a trial of CY200 in CRPS Type 1 to the UK MHRA.
The multicentre, randomised, double-blind, placebo-controlled UK study will assess CY200’s analgesic efficacy, safety and tolerability in adults with CRPS Type 1. The submission marks a step towards starting the Phase...
Cayman Chemical Company has applied to the Drug Enforcement Administration to register as a bulk manufacturer of basic classes of controlled substances.
The Drug Enforcement Administration published the application on 24 September 2026. Comments are open for 60 days, ending on 23 November 2026, but no specific controlled substances are identified in the provided mater...
Cambridge Isotope Laboratories, Inc. has applied to register as an importer of basic classes of controlled substances.
The application was submitted to the Drug Enforcement Administration and published on 24 September 2026. Further information on the drugs covered is provided in the supplementary information.
Psilocybin may help the brain recover from concussion, new study finds
A concussion is often described as a "mild" traumatic brain injury. Yet repeated blows to the head rarely feel mild, and their effects—including changes in movement, memory, mood and brain function—may last for months...
First fMRI study of mescaline reveals altered sensory filtering and brain networks
A groundbreaking brain imaging study in awake rats reveals that the psychedelic mescaline uniquely alters brain function. The drug reduces cerebellum activity while boosting global connectivity, shifting how the brain...
The Oldest Ayahuasca Researchers Weren’t in Labs
At the World Ayahuasca Forum, Indigenous science was treated as science in its own right. [...] Read More...
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders,…
The Drug Enforcement Administration proposed placing five tryptamine hallucinogens, including 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT, into Schedule I.
The proposed rule, dated 23 September 2026, covers the five named tryptamines and their salts, isomers and salts of isomers. The comment period ends on 23 October 2026.
Clearmind Medicine announced the US publication of three patent applications covering LSD, ketamine and ibogaine combinations with N-acylethanolamines for potential therapeutic uses.
The applications cover combinations involving palmitoylethanolamide, or PEA, for potential use in depression, PTSD, pain and substance use disorders, including alcohol use disorder. The filings expand Clearmind’s inte...
Psilocybin and Contrasting Musical Compositions: Effects on Music-Evoked Emotional Responses in Healthy Adults
This exploratory preprint analysed music responses from a double-blind, placebo-controlled psilocybin crossover trial (0.26 mg/kg). Part 1 (n=19) screened eight compositions; Part 2 (n=17) compared emotional responses...